Kern D E, Kidd P G, Moe R, Hanke D, Olerud J E
Department of Medicine, University of Washington School of Medicine, Seattle, USA.
Arch Dermatol. 1998 Feb;134(2):158-64. doi: 10.1001/archderm.134.2.158.
To determine the prognostic value of analyzing lymph node (LN) DNA from patients with mycosis fungoides for the presence of a monoclonal T-cell population.
Inception cohort study.
A tertiary care referral center in Seattle, Wash.
Fifty-five uniformly staged patients with the diagnosis of mycosis fungoides and who had a lymph node biopsy, 21 with clinically abnormal nodes and 34 with normal nodes.
Lymph nodes were evaluated by Southern blot analysis for T-cell receptor beta-chain (TCRB) gene rearrangement and by histopathologic examination for the LN classification using the National Cancer Institute system. Patients were observed clinically for a mean (+/- SD) of 4.7 +/- 3.4 years.
Patients with detectable TCRB gene rearrangement in lymph node DNA had an increased likelihood of a poor clinical outcome and a decreased probability of survival (P < .001 for both) compared with patients with the TCRB germline. Although patients with clinically enlarged nodes were more likely to have the TCRB gene rearranged, those with normal nodes and the TCRB gene rearranged also had a poor clinical outcome and a decreased probability of survival. Similar to those with the TCRB gene rearranged, most patients with advanced histopathologic changes (LN3 and LN4) had a poor prognosis. The presence of a rearranged TCRB gene, however, correctly predicted some patients with intermediate LN scores (LN2) who had a poor clinical outcome.
Detection of a monoclonal T-cell population, as demonstrated by a rearranged TCRB gene on Southern blot analysis, in LNs of patients with mycosis fungoides is predictive of a poor clinical outcome and a reduced probability of survival. Lymph node TCRB gene analysis provides additional prognostic information for patients with mycosis fungoides with intermediate LN histopathology.
确定分析蕈样肉芽肿患者淋巴结(LN)DNA中是否存在单克隆T细胞群体的预后价值。
起始队列研究。
华盛顿州西雅图的一家三级医疗转诊中心。
55例诊断为蕈样肉芽肿且进行了淋巴结活检的分期一致的患者,其中21例临床淋巴结异常,34例淋巴结正常。
通过Southern印迹分析评估淋巴结的T细胞受体β链(TCRB)基因重排,并使用美国国立癌症研究所系统通过组织病理学检查对淋巴结进行分类。对患者进行平均(±标准差)4.7±3.4年的临床观察。
与TCRB种系的患者相比,淋巴结DNA中可检测到TCRB基因重排的患者临床预后不良的可能性增加,生存概率降低(两者P均<0.001)。虽然临床淋巴结肿大的患者更有可能发生TCRB基因重排,但淋巴结正常且TCRB基因重排的患者临床预后也较差,生存概率降低。与TCRB基因重排的患者相似,大多数具有晚期组织病理学改变(LN3和LN4)的患者预后不良。然而,重排的TCRB基因能正确预测一些LN评分中等(LN2)且临床预后不良的患者。
Southern印迹分析显示蕈样肉芽肿患者淋巴结中重排的TCRB基因所证实的单克隆T细胞群体的检测可预测临床预后不良和生存概率降低。淋巴结TCRB基因分析为具有中等LN组织病理学的蕈样肉芽肿患者提供了额外的预后信息。